These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22414465)

  • 1. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction.
    Kofoed SC; Muhic A; Baeksgaard L; Jendresen M; Gustafsen J; Holm J; Bardram L; Brandt B; Brenø J; Svendsen LB
    Scand J Surg; 2012; 101(1):26-31. PubMed ID: 22414465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
    Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
    Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
    Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
    Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
    Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
    Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.
    Kim Y; Squires MH; Poultsides GA; Fields RC; Weber SM; Votanopoulos KI; Kooby DA; Worhunsky DJ; Jin LX; Hawkins WG; Acher AW; Cho CS; Saunders N; Levine EA; Schmidt CR; Maithel SK; Pawlik TM
    Surgery; 2017 Aug; 162(2):285-294. PubMed ID: 28578142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction.
    Anderegg MC; Lagarde SM; Jagadesham VP; Gisbertz SS; Immanuel A; Meijer SL; Hulshof MC; Bergman JJ; van Laarhoven HW; Griffin SM; van Berge Henegouwen MI
    Ann Surg; 2016 Nov; 264(5):847-853. PubMed ID: 27429034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
    Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
    Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience.
    Hughes BG; Yip D; Chao M; Gibbs P; Carroll S; Goldstein D; Burmeister B; Karapetis C
    ANZ J Surg; 2004 Nov; 74(11):951-6. PubMed ID: 15550081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    Macdonald JS; Smalley SR; Benedetti J; Hundahl SA; Estes NC; Stemmermann GN; Haller DG; Ajani JA; Gunderson LL; Jessup JM; Martenson JA
    N Engl J Med; 2001 Sep; 345(10):725-30. PubMed ID: 11547741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
    Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
    Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multimodality therapy for adenocarcinoma of the esophagogastric junction].
    He J; Huang JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Sep; 15(9):877-80. PubMed ID: 22990915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.
    Fuentes E; Ahmad R; Hong TS; Clark JW; Kwak EL; Rattner DW; Mullen JT
    J Surg Oncol; 2016 Apr; 113(5):560-4. PubMed ID: 26792144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction].
    Ben Salah H; Bahri M; Dhouib F; Daoud J
    Cancer Radiother; 2016 Dec; 20(8):830-832. PubMed ID: 27793531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemoradiotherapy in gastric cancer and carcinoma of the oesophago-gastric junction.
    Stahl M
    Onkologie; 2004 Feb; 27(1):33-6. PubMed ID: 15007246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction.
    van de Ven C; De Leyn P; Coosemans W; Van Raemdonck D; Lerut T
    Eur J Cardiothorac Surg; 1999 Jun; 15(6):769-73. PubMed ID: 10431857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
    Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
    Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
    J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study.
    Kaytan Saglam E; Yucel S; Balik E; Saglam S; Asoglu O; Yamaner S; Bugra D; Oral EN; Kizir A; Kapran Y; Sakar B; Akyuz A; Gulluoglu M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):361-7. PubMed ID: 25189794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness in esophagogastric cancer.
    Knab LM; Belotte J; Munshi HG; Bentrem DJ
    Cancer Treat Res; 2015; 164():121-42. PubMed ID: 25677022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of the lymph node count after neoadjuvant treatment for rectal cancer.
    Persiani R; Biondi A; Gambacorta MA; Bertucci Zoccali M; Vecchio FM; Tufo A; Coco C; Valentini V; Doglietto GB; D'Ugo D
    Br J Surg; 2014 Jan; 101(2):133-42. PubMed ID: 24375303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.